GAITHERSBURG, Md., March 15 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) announced today that it has added five new vice presidents to
its management team. The newly hired team members include Allan Darling,
Ph.D., vice president, corporate quality control; Gary B. Ebbert, Ph.D., vice
president, antibody and small molecule manufacturing; Bahija Jallal, Ph.D.,
vice president, translational sciences; and Douglas B. Willner, vice
president, sales training. MedImmune also promoted Frank D. Czworka, Jr.,
formerly regional business director, to vice president, sales, infectious
"MedImmune continues to vest our successful leaders with increasing levels
of responsibility. Frank Czworka has made substantial contributions to our
sales organization over the past six years and will have an increased
opportunity to contribute to our future through his new role leading our
infectious disease sales force," said David M. Mott, chief executive officer
and president. "We also continue to attract world-class talent to MedImmune as
evidenced by the additions of Drs. Darling, Ebbert and Jallal and Mr. Willner
to our organization. We are excited to have these dynamic and talented
individuals join our team and look forward to their contributions to our
New Executives at MedImmune
Allan Darling, Ph.D., joins MedImmune as vice president, corporate quality
control, with primary responsibility for overseeing quality control at the
company's commercial production facilities in support of antibody, vaccine and
small molecule manufacturing activities. Prior to joining MedImmune, Dr.
Darling was employed by BioReliance Invitrogen Bioservices where he held
several positions of increasing responsibility, leading to his most recent
role as vice president, global operations. Previously, Dr. Darling held
positions at United Kingdom-based companies and institutions such as Q-One
Biotech, the Beatson Institute for Cancer Research and the Medical Research
Council in Glasgow. Dr. Darling holds a bachelor's degree in biological
sciences from the University of Edinburgh and a doctorate from the University
Gary B. Ebbert, Ph.D., has been appointed vice president, antibody and
small molecule manufacturing for MedImmune where he is responsible for all
antibody and small molecule commercial manufacturing activities at the
company's production facilities. He will also ensure regulatory compliance for
the company's manufacturing operations and will lead infrastructure
enhancements in support of future growth in this area. Dr. Ebbert joins
MedImmune from King Pharmaceuticals, Inc. where he served as executive vice
president, worldwide manufacturing. Previously, Dr. Ebbert was president and
chief executive officer of Ebquest Healthcare, Inc. Dr. Ebbert also served as
the corporate vice president, technology at Sanofi-Pasteur (formerly Aventis
Pasteur) where he was responsible for identifying, evaluating and
incorporating new technology into the company's global industrial operations.
Prior to his position as corporate vice president, Dr. Ebbert served as vice
president, operations at Aventis Pasteur. Dr. Ebbert earned his doctorate from
Temple University in pharmaceutics and his master's degree in biological
science with a concentration in molecular/cell biology from East Stroudsburg
University in Pennsylvania.
Bahija Jallal, Ph.D., will join MedImmune as vice president, translational
sciences. In her new role, Dr. Jallal will develop the translational sciences
group to assess biomarkers and establish a preclinical knowledge base for
MedImmune's therapeutic agents that will guide clinical studies. She will also
direct the toxicology/pathology, clinical assays and in vivo/ex vivo biology
efforts for MedImmune. Dr. Jallal joins MedImmune from Chiron Corporation
where she served as vice president, drug assessment and development. She also
successfully established the translational medicine group at Chiron.
Previously, Dr. Jallal worked at Sugen, Inc. where she held positions of
increasing responsibility until her departure. Dr. Jallal received a master's
degree in biology from the Universite de Paris VII in France, and her
doctorate in physiology from the University of Pierre & Marie Curie in Paris.
She conducted her postdoctoral research at the Max Planck Institute of
Biochemistry in Martinsried, Germany.
Douglas B. Willner has joined MedImmune as vice president, sales training
where he is responsible for building and managing the various sales training
programs. Mr. Willner joins MedImmune from Serono, Inc. where he served as
executive director, learning and organizational excellence. Previously, Mr.
Willner was director, leadership and development, for GlaxoSmithKline Consumer
Healthcare. He also has extensive experience in sales, sales management, human
resources and operations. Mr. Willner holds a bachelor of science in business
and economics from the University of Connecticut.
In his new position as vice president, sales, infectious disease, Frank D.
Czworka, Jr. will lead sales force activities for MedImmune's infectious
disease medicines. Mr. Czworka joined MedImmune in May 2000 as an area
business manager leading the biotechnology sales specialist launch operations
in Georgia, Alabama and Florida. In July 2001, he was promoted to regional
business director for the Northeast region where he managed personnel
expansion from 39 representatives to its current size of nearly 100
representatives. Prior to joining MedImmune, Mr. Czworka held a number of
positions at TAP Pharmaceuticals, including professional sales representative,
government account manager, regional and home office program training manager
and district sales manager. Mr. Czworka holds a bachelor of science and arts
degree in marketing from the University of Central Florida.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,200 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
SOURCE MedImmune, Inc.
CONTACT: Media: Kathryn Barrett, +1-301-398-4320 or Clarencia Stephen,
+1-301-398-4073, Investors: Peter Vozzo, +1-301-398-4358, all of MedImmune,